Lead Product(s) : Selenium Sulfide
Therapeutic Area : Ophthalmology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Azura Enrolls First Patient in Phase 3 Trial for MGD Treatment AZR-MD-001
Details : AZR-MD-001 is an ophthalmic ointment, applied directly to the meibomian glands. It is under clinical development for the patients with Contact Lens Discomfort & Meibomian Gland Dysfunction.
Product Name : AZR-MD-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 06, 2024
Lead Product(s) : Selenium Sulfide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Selenium Sulfide
Therapeutic Area : Ophthalmology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AZR-MD-001 is an easy-to-use ophthalmic ointment preparation applied directly to the meibomian glands in the lower eyelid. It is under phase 3 clinical development for the patients with Contact Lens Discomfort (CLD) & Meibomian Gland Dysfunction (MGD).
Product Name : AZR-MD-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 18, 2023
Lead Product(s) : Selenium Sulfide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Selenium Sulfide
Therapeutic Area : Ophthalmology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AZR-MD-001 0.5% meets co-primary efficacy endpoints, making it the first investigational drug to show significant improvements in both signs and symptoms of Meibomian Gland Dysfunction.
Product Name : AZR-MD-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 17, 2022
Lead Product(s) : Selenium Sulfide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Selenium Sulfide
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U.S. and European Patents
Details : AZR-MD-001 harnesses the power of selenium sulfide (SeS2) in an easy-to-use ophthalmic ointment preparation applied directly to the meibomian glands on the eye lid.
Product Name : AZR-MD-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2022
Lead Product(s) : Selenium Sulfide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Selenium Sulfide
Therapeutic Area : Ophthalmology
Study Phase : Phase II/ Phase III
Sponsor : CUREator
Deal Size : Undisclosed
Deal Type : Funding
Details : The grant will support Azura’s two-stage study evaluating the safety, tolerability and efficacy of the company’s lead clinical candidate, AZR-MD-001, in patients with contact lens discomfort (CLD) who show evidence of Meibomian gland dysfunction (MGD...
Product Name : AZR-MD-001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 09, 2022
Lead Product(s) : Selenium Sulfide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II/ Phase III
Sponsor : CUREator
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Selenium Sulfide
Therapeutic Area : Ophthalmology
Study Phase : Phase II/ Phase III
Sponsor : OrbiMed
Deal Size : $20.0 million
Deal Type : Financing
Details : On the back of encouraging Phase 2 data to date proceeds from the funding round will be used to advance Azura’s lead product candidate AZR-MD-001 through a registration study for the treatment of MGD.
Product Name : AZR-MD-001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 22, 2020
Lead Product(s) : Selenium Sulfide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II/ Phase III
Sponsor : OrbiMed
Deal Size : $20.0 million
Deal Type : Financing
Reset All
